Ingredion (INGR) Reaffirmed Its 2026 Guidance, Is The Stock Fully Valued?

Why Ingredion stock is back in focus after fresh guidance

Ingredion (INGR) put out second quarter 2026 results alongside new third quarter guidance and a reaffirmed full year outlook, giving investors updated figures on sales, earnings and profitability.

The company now expects third quarter net sales to be up low single digits compared with a year earlier, with full year 2026 sales projected to be flat to up low single digits and reported EPS guided to a range of $9.15 to $9.75.

Management also signaled that reported operating income for 2026 is expected to be down low double digits, reflecting volume growth and favorable foreign exchange, offset by lower price mix and the earlier sale of a majority stake in its Pakistan business.

See our latest analysis for Ingredion.

Ingredion shares have picked up in the short term, with a 7 day share price return of 4.9% and a 30 day share price return of 5.65%, yet the 1 year total shareholder return is down 14.82% even though the 5 year total shareholder return is up 35.93%. This suggests near term momentum has improved while longer term investors have seen more modest gains relative to recent weakness.

If you are weighing Ingredion's updated guidance against other ideas in the market, it could be a good moment to broaden your watchlist with 19 top founder-led companies

Ingredion shares have rebounded in the past month while earnings guidance points to flat to modest sales growth and lower operating income. Is this the moment to commit fresh capital, or is it better to wait for a clearer entry after volatility settles?

Most Popular Narrative: 18.2% Overvalued

Ingredion last closed at $104.33, while the most followed narrative calculates a fair value of $88.23 using a discounted cash flow approach with a 7.108% discount rate. That gap frames the debate around whether recent share price strength has moved ahead of the long term cash flow outlook.

The acquisition of Tate & Lyle has the potential to transform Ingredion from a predominantly commodity-oriented starch and sweetener processor into a more global specialty ingredients platform. The primary upside comes from mix shift toward higher-margin functional ingredients, meaningful cross-selling opportunities with global CPG customers, and scale-driven cost synergies. If successfully integrated, the combined business could generate structurally higher margins, stronger free cash flow, and warrant a higher valuation multiple over time.

Read the complete narrative.

Want to see how this Ingredion thesis turns into a specific price tag? The narrative focuses on margin expansion, steady revenue compounding, and a richer future earnings multiple. Curious which building blocks matter most?

Result: Fair Value of $88.23 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Ingredion's story could be knocked off course if the Tate & Lyle integration underdelivers or if specialty growth fails to offset pressure in commodity sweeteners.

Find out about the key risks to this Ingredion narrative.

Another View on Ingredion valuation

The narrative DCF suggests Ingredion is 18.2% overvalued at $104.33 versus a fair value of $88.23. Our SWS DCF model points in the opposite direction and estimates fair value at $222.69, which is 53.2% above the current share price. Which set of assumptions do you trust more, and why?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With mixed signals around Ingredion's valuation and outlook, it makes sense to review the underlying data yourself and move quickly to form your own judgement. To understand what the market currently views as the main positives around the stock, start by reviewing the 4 key rewards.

Looking for more investment ideas beyond Ingredion?

If Ingredion has sharpened your focus on quality and timing, do not stop here. Broaden your opportunity set now or you could miss more compelling setups.

• Target potential mispriced quality by scanning companies on the 52 high quality undervalued stocks and see which stocks currently line up with your return expectations.
• Strengthen your income stream by reviewing the 8 dividend fortresses and spot payouts that may better fit your long term cash flow goals.
• Prioritize resilience by checking the 83 resilient stocks with low risk scores and identify stocks that could help steady your portfolio when markets turn choppy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com